Investors

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, Zalviso, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the complexity of infusion pumps. AcelRx has announced positive results from each of the three Phase 3 clinical trials for Zalviso and has submitted an NDA to the FDA seeking its approval. AcelRx also announced positive top-line results for a Phase 2 trial for ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from U.S. Army Medical Research and Materiel Command. The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development.
ACRX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$10.68
Change (%) Stock is Up 0.45 (4.40%)
Volume799,999
Data as of 04/17/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

    More >>
04/04/14AcelRx Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference
REDWOOD CITY, Calif., April 4, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO, and Timothy E. Morris, CFO, will present a Company update on April 9th. Presentation details are as follows: 13th Annual Needham Healthcare Conference   Date:  Wednesday, April 9, 2014  ... 
Printer Friendly Version
03/25/14AcelRx Pharmaceuticals Appoints Timothy E. Morris as Chief Financial Officer
REDWOOD CITY, Calif., March 25, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the appointment of Timothy E. Morris as chief financial officer (CFO).  Mr. Morris brings 30 years of professional finance and accounting experience to AcelRx, 18 of those years spent in the role of chief financial officer, most... 
Printer Friendly Version
03/07/14AcelRx Pharmaceuticals to Participate at the 26th Annual Roth Conference
REDWOOD CITY, Calif., March 7, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO will present a Company update at the following conference: 26th Annual Roth Conference Date:  Tuesday, March 11, 2014 Location:  The Ritz Carlton, Laguna Niguel, CA Presentation Time:  1... 
Printer Friendly Version

Upcoming Events

    More >>
DateTitle
05/06/14
AcelRx Pharmaceuticals, Inc. at Mizuho Securities USA Healthcare Corporate Access Day
LocationNew York City, NY US
05/20/14 10:30 a.m. ET
AcelRx Pharmaceuticals, Inc. at UBS Global Healthcare Conference
LocationNew York, NY US
06/02/14
through
06/05/14
AcelRx Pharmaceuticals, Inc. at Jefferies 2014 Global Healthcare Conference
LocationThe Grand Hyatt New York
New York, NY US

Receive E-mail Alerts 

Sign up to receive e-mail alerts whenever AcelRx Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

AcelRX

CONTACT